Press Releases 15th Congress of the EHA

Hodgkin Lymphoma (HL); how can we do better with fewer side effects?

Barcelona, June 11 2010. At the 15th Congress of EHA in Barcelona the EHA Jean Bernard Lifetime Achievement Award will be handed to Dr Emili Montserrat and the EHA José Carreras Award to Dr Brunangelo Falini.

Barcelona, June 11, 2010. Drugs which reverse epigenetic abnormalities are looking very promising in the treatment of some blood cancers and may have a role to play in solid tumors such as lung cancer. These research results are being presented at the 15th Congress of the European Hematology Association (EHA) in Barcelona.

Barcelona, June 11 2010. Results from the RE-NOVATE® II clinical trial presented today at the 15th Congress of the European Hematology Association (EHA) have shown that the drug dabigatran etexilate 220mg taken once daily is as effective and safe as enoxaparin 40mg in preventing venous thromboembolism (VTE) (blood clots in the leg veins) after total hip replacement surgery. The results also showed that the drug dabigatran etexilate significantly reduced the number of major blood clots and deaths from blood clots when compared to enoxaparin.

Maintenance Therapy with Rituximab, a Most Potent Anti-Lymphoma Antibody, Halves Risk of Lymphoma Recurrence.

Barcelona, June 11 2010. Research has shown that stem cells can cure Fanconi Anemia, a genetic disorder that might reduce life expectancy by twenty years. It was demonstrated that following correction of the genetic defect cells from patients with Fanconi Anemia can be reprogrammed to make healthy stem cells. These results are presented at the 15th Congress of the European Hematology Association in Barcelona.